Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prempro Osteoporosis Use In Older Women May Be Limited To Second-Line

Executive Summary

Wyeth is considering revising Prempro's indication to more clearly define the hormone therapy as second-line osteoporosis prevention for older women

You may also be interested in...



Hormone Therapy Osteoporosis Approval Hurdle Unchanged By WHI, FDA Says

Hormone therapy drug sponsors seeking approval for osteoporosis do not need to submit to FDA any extraordinary safety data in light of the WHI findings, Metabolic & Endocrine Division Director David Orloff, MD, said Oct. 7

Hormone Therapy Osteoporosis Approval Hurdle Unchanged By WHI, FDA Says

Hormone therapy drug sponsors seeking approval for osteoporosis do not need to submit to FDA any extraordinary safety data in light of the WHI findings, Metabolic & Endocrine Division Director David Orloff, MD, said Oct. 7

Wyeth Prempro Gets Dementia Warning; FDA Considering HRT Class Labeling

FDA is considering hormone replacement therapy class labeling that would incorporate data from a WHI sub-study showing twice the rate of dementia in patients taking Wyeth's Prempro estrogen/progestin combo

UsernamePublicRestriction

Register

PS042627

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel